- Home
- DRUG vs SRG Comparison
DRUG vs SRG Comparison
Compare DRUG & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- SRG
- Stock Information
- Founded
- DRUG 2019
- SRG 2014
- Country
- DRUG United States
- SRG United States
- Employees
- DRUG N/A
- SRG N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- SRG Real Estate Investment Trusts
- Sector
- DRUG Health Care
- SRG Real Estate
- Exchange
- DRUG Nasdaq
- SRG Nasdaq
- Market Cap
- DRUG 233.2M
- SRG 218.9M
- IPO Year
- DRUG N/A
- SRG 2015
- Fundamental
- Price
- DRUG $33.19
- SRG $2.93
- Analyst Decision
- DRUG Strong Buy
- SRG
- Analyst Count
- DRUG 5
- SRG 0
- Target Price
- DRUG $83.25
- SRG N/A
- AVG Volume (30 Days)
- DRUG 25.6K
- SRG 354.0K
- Earning Date
- DRUG 05-20-2025
- SRG 05-20-2025
- Dividend Yield
- DRUG N/A
- SRG N/A
- EPS Growth
- DRUG N/A
- SRG N/A
- EPS
- DRUG N/A
- SRG N/A
- Revenue
- DRUG N/A
- SRG $14,568,000.00
- Revenue This Year
- DRUG N/A
- SRG N/A
- Revenue Next Year
- DRUG N/A
- SRG N/A
- P/E Ratio
- DRUG N/A
- SRG N/A
- Revenue Growth
- DRUG N/A
- SRG N/A
- 52 Week Low
- DRUG $0.93
- SRG $2.43
- 52 Week High
- DRUG $79.02
- SRG $9.37
- Technical
- Relative Strength Index (RSI)
- DRUG 51.77
- SRG 49.74
- Support Level
- DRUG $29.59
- SRG $2.87
- Resistance Level
- DRUG $32.75
- SRG $2.99
- Average True Range (ATR)
- DRUG 1.99
- SRG 0.11
- MACD
- DRUG 0.14
- SRG 0.03
- Stochastic Oscillator
- DRUG 54.42
- SRG 60.00
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management and leasing of diversified and mixed-use properties throughout the United States.